Loading
Loading
Research Overview
Synthetic analogue of the first 29 amino acids of GHRH; binds pituitary GHRH receptors to stimulate pulsatile GH release. Historically used for paediatric growth hormone deficiency.
Overview
Sermorelin (GHRH 1-29 NH2) is the N-terminal fragment of human growth hormone-releasing hormone that retains full biological activity at the GHRH receptor. Preclinical research has used sermorelin to study pituitary somatotroph biology, growth hormone secretion dynamics, and the downstream consequences of amplified GH axis activity in laboratory animal models. Its shorter sequence compared to full-length GHRH has made it a convenient research tool for investigating GH-axis biology.
In preclinical endocrinology research, sermorelin has been studied for its ability to stimulate episodic growth hormone release from pituitary somatotrophs through GHRH receptor-mediated cAMP signalling. Animal model studies have examined the pulsatile nature of sermorelin-stimulated GH secretion, its dose-response characteristics, and the relationship between GHRH receptor activity and downstream IGF-1 production in relevant model systems.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, sermorelin (ghrh analogue) peptide has no TGA approval for therapeutic use. It is sold by Capital Precision Labs strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Synthetic analogue of the first 29 amino acids of GHRH; binds pituitary GHRH receptors to stimulate pulsatile GH release. Historically used for paediatric growth hormone deficiency.
Support
For research use only. Capital Precision Labs products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
